Share on StockTwits

Cynapsus Therapeutics (CVE:CTH) issued its quarterly earnings data on Thursday. The company reported ($0.04) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.02) by $0.02, StockRatingsNetwork reports.

Cynapsus Therapeutics Inc is a specialty pharmaceutical company developing non-injectable delivery of apomorphine to be used as a rescue therapy for off motor symptoms of Parkinson’s disease.

Receive News & Ratings for Cynapsus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynapsus Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.